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α-Synuclein (α-Syn) aggregation is a pathological feature of synucleinopathies,
neurodegenerative disorders that include Parkinson’s disease (PD). We
have tested whether N,N,N′,N′-tetramethyl-10H-phenothiazine-3,7-diaminium
bis(hydromethanesulfonate) (leuco-methylthioninium bis(hydromethanesulfonate);
LMTM), a tau aggregation inhibitor, affects α-Syn aggregation in vitro and in vivo.
Both cellular and transgenic models in which the expression of full-length human
α-Syn (h-α-Syn) fused with a signal sequence peptide to promote α-Syn aggregation
were used. Aggregated α-Syn was observed following differentiation of N1E-115
neuroblastoma cells transfected with h-α-Syn. The appearance of aggregated α-Syn
was inhibited by LMTM, with an EC50 of 1.1 µM, with minimal effect on h-α-Syn mRNA
levels being observed. Two independent lines of mice (L58 and L62) transgenic for
the same fusion protein accumulated neuronal h-α-Syn that, with aging, developed
into fibrillary inclusions characterized by both resistance to proteinase K (PK)-cleavage
and their ability to bind thiazin red. There was a significant decrease in α-Syn-positive
neurons in multiple brain regions following oral treatment of male and female mice with
LMTM administered daily for 6 weeks at 5 and 15 mg MT/kg. The early aggregates
of α-Syn and the late-stage fibrillar inclusions were both susceptible to inhibition by
LMTM, a treatment that also resulted in the rescue of movement and anxiety-related
traits in these mice. The results suggest that LMTM may provide a potential disease
modification therapy in PD and other synucleinopathies through the inhibition of α-Syn
aggregation.
Keywords: aggregation inhibitor, leucomethylthioninium, mouse model, Parkinson’s disease, α-synuclein,
synucleinopathy
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INTRODUCTION
Protein conformational disorders are a group of diseases
which evolve due to protein misfolding leading to the
formation of aggregated structures (Carrell and Gooptu, 1998;
Uversky and Fink, 2004; Lashuel et al., 2013). PD and
dementia with Lewy bodies are the most common disorders
associated with synuclein pathology and are characterized by
intra-neuronal deposits of α-Syn fibrils most prominently found
in midbrain regions and cerebral cortex (Uversky, 2003). This
pathology spreads progressively from medulla oblongata through
midbrain to neocortex (Braak et al., 2003). The monomeric
α-Syn is a protein of 140 amino acids that undergoes a
conformational change associated with the formation of dimers
and oligomers and, ultimately, pre-fibrils and insoluble fibrils
(Uversky and Fink, 2004; Lashuel et al., 2013). Mutations in
the α-synuclein gene (SNCA), e.g., A53P, A53T, and E46K,
promote self-oligomerisation and are associated with dominantly
inherited PD (Uversky and Fink, 2004; Lashuel et al., 2013).
We have developed two transgenic mouse models of
synucleinopathy, h-α-SynL58 and h-α-SynL62, termed L58 and
L62, respectively. In both, full-length h-α-Syn fused with an
N-terminal signal sequence peptide, is expressed under the
control of theThy1-promotor. The signal sequence peptide serves
as a membrane targeting sequence that directs proteins to the
endoplasmic reticulum (Partridge et al., 1999; Harrington et al.,
2015; Melis et al., 2015b). A detailed characterisation of L58
and L62 is reported separately (Frahm et al., 2017). There is
intra-neuronal expression of h-α-Syn in both neocortex and
archicortex in these mouse lines, and both are associated with a
behavioral hypoactivity state.
Although levodopa remains the most effective treatment of
PD, side effects such as motor fluctuations and dyskinesia limit
its long-term use. Alternative approaches targeting α-Syn include
enhancement of autophagy, modulation of phosphorylation,
and slowing or ameliorating the production, deposition and
aggregation of pathological proteins (Dehay et al., 2015).
This presents several new therapeutic targets, including active
or passive immunization these have been summarized by
Velayudhan et al. (2017). Interference with anti-parallel folding
of α-Syn and/or disaggregation of existing oligomers are of
particular interest. Polyphenols and peptides containing mutated
segments of the hydrophobic central region of α-Syn, and
tyrosine or tryptophan-rich β-hairpins, have been reported to
inhibit synuclein aggregation (for examples, see Sivanesam et al.,
2015). Inhibition of the cytotoxic A11 epitopes of synuclein
by triphenylmethane dyes such as Coomassie Brilliant Blue
R disrupts existing fibrils and reduces fibrillisation (Ahsan
et al., 2017), but none of the above molecules has been
Abbreviations: AC + VC, auditory cortex and visual cortex; db-cAMP, dibutyryl
cyclic AMP; DCE, dichloroethane; DpMe+MGV, deep mesencephalic and
medial geniculate nuclei; h-α-Syn, human α-synuclein; Hip+S, hippocampus
and subiculum; InG, intermediate grey layer of the superior colliculus; LMTM,
leucomethylthioninium bis(hydromethanesulfonate); MC, motor cortex; MT,
methylthioninium; NGF, nerve growth factor; PD, Parkinson’s disease; RMC,
magnocellular part of the red nucleus; SMC, primary sensorimotor cortex; SNpR,
substantia nigra pars reticulata.
tested in clinical trials. Methylthioninium chloride (MTC) and
leuco-methylthioninium bis(hydromethanesulfonate) (LMTM)
are effective as protein aggregation inhibitors for both tau and
α-Syn in vitro (Wischik et al., 1996; Taniguchi et al., 2005;
Masuda et al., 2006; Harrington et al., 2015) and are capable
of rescuing behavioral deficits and ameliorating pathology in
transgenic mouse models of tau protein aggregation (Melis et al.,
2015a). Both forms of the methylthioninium (MT) moiety have
been tested clinically in Alzheimer’s disease in Phase 2 and 3
clinical trials (Wischik et al., 2015; Gauthier et al., 2016; Wilcock
et al., 2018) and have been found to have potential efficacy as
monotherapy. LMTM is a stable reduced form of the MT moiety,
which is better absorbed than MTC over a wide dosing range.
We now report that LMTM inhibits α-Syn aggregation in
N1E-115 neuroblastoma cells expressing human α-Syn and in
cortical neurons of transgenic L58 and L62 mice. Amelioration
of h-α-Syn pathology was associated with normalization of
behavioral deficits in L62 mice.
MATERIALS AND METHODS
LMTM and Antibodies
N,N,N′,N′-tetramethyl-10H-phenothiazine-3,7-diaminium bis
(methanesulfonate) (leuco-methylthioninium bis(hydro-
methanesulfonate); LMTM) was supplied by TauRx Therapeutics
Ltd., Singapore.
A list of the α-Syn antibodies used in this study, their epitopes
and source, is given in Table 1.
Cellular h-α-Syn Model
N1E-115 mouse neuroblastoma cells were modified to
constitutively express full-length h-α-Syn fused with an
N-terminal signal sequence peptide (SSFsyn) (DH60.21 clone;
pcDNA3.1 vector). Cells were grown at 37◦C in an atmosphere
containing 5% CO2 in Dulbecco’s modified Eagle’s medium
with 1% GlutaMAX I (1%), pyruvate and glucose (4.5 g/L) (Life
Technologies, Paisley, United Kingdom) supplemented with
10% fetal calf serum (Sigma–Aldrich, Dorset, United Kingdom),
penicillin (50 U/ml), streptomycin (50 µg/mL) and G418
(300 µg/mL; for maintenance of the plasmid). Transgene
expression was induced by differentiation of the cells either by
depletion of serum or by addition of either NGF (100 µg/mL)
or dibuytryl cyclic AMP (db-cAMP; 1 mM) to serum-depleted
medium. Cells were immunostained 72 h after induction, using
anti-α-Syn antibodies as indicated. Goat anti-mouse IgG:FITC-
conjugate (Sigma–Aldrich) was used as secondary antibody.
Specimens were mounted with Vectashield Antifade Reagent
(Vector Laboratories, Peterborough, United Kingdom) and
examined by fluorescence microscopy (Axiomat; Carl Zeiss,
Jena, Germany).
Transfected DH60.21 cells, in culture medium containing
fetal calf serum (1%) and db-cAMP (1 mM), were treated
with LMTM at five concentrations in triplicate. After 72 h
incubation, medium was removed, cells were washed with
PBS and collected in Laemmli SDS-PAGE sample buffer.
Samples were separated by Tris-glycine SDS-PAGE, using
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TABLE 1 | Description of α-Syn antibodies.
Antibody Species/Class Immunogen Epitope (specificity) Source (catalog number)
mAb 42 Mouse IgG1 rat-α-Syn 15–123 BD Biosciences, Oxford, United Kingdom (610787)
mAb 204 Mouse IgG2a h-α-Syn 95∼109∗ Santa Cruz Biotechnology, Dallas, TX, United States (sc-32280)
mAb 211 Mouse IgG1 h-α-Syn 121–125 peptide 121∼125 Santa Cruz Biotechnology (sc-12767)
mAb 559 Mouse IgG1 h-α-Syn 109∼140∗ AMS Biotechnology, Abingdon, United Kingdom
mAb 874 Mouse IgG1 h-α-Syn 109∼140∗ AMS Biotechnology
mAb 3H2897 Mouse IgG1 h-α-Syn 1–140 Santa Cruz Biotechnology (sc-69977)
mAb D37A6 Rabbit IgG mouse-α-Syn 100–110 peptide 100∼110 (Mouse/rat-specific) Cell Signaling Technology, Leiden, Netherlands (4179)
∗Epitope mapping by immunoassay against recombinant and synthetic peptides in this study.
a minigel system (BioRad Laboratories, Hemel Hempstead,
United Kingdom). Proteins were transferred in N-cyclohexyl-
3-aminopropanesulfonic acid (CAPS) buffer to polyvinylidene
difluoride (PVDF) membrane and α-Syn detected on
immunoblots with mAb 42 and enhanced chemiluminescence,
and images captured using a Biospectrum 810 (UVP, Cambridge,
United Kingdom). Samples from DH60.21 cells were separated
by SDS-PAGE in duplicate side-by-side. One replicate was
transferred to PVDF, and developed using mAb204. The
other gel was fixed in acetic acid/ethanol and stained with
silver, according to Nebrich et al. (2007). The stained gel was
overlaid on the hyperfilm and spots, from silver-stained gel and
corresponding to immunoreactive spots on film, were exicised
from gel, digested with trypsin and measured with Q-Exactive
Orbitrap. We detected no synuclein sequence in the 50-kDa
band, whereas synuclein was identified in the 19-kDa synuclein
band. The presence of a non-specific, non-synuclein band labeled
with mAb 42 was used as an internal control for cell density in
each replicate. The ratio of the intensities of the α-Syn band to
the non-specific band were normalized to non-differentiated
cells without drug treatment. The EC50 value was determined as
the concentration at which this ratio is decreased by 50%.
Proteins were extracted from cells by sequential solubilisation
using methods described by Masuda et al. (Masuda et al., 2006).
DH60.21 cells were collected by centrifugation (350× g for 5 min
at 4◦C), washed with PBS, and homogenized in Tris-HCl (30 mM;
pH 7.5) with or without Triton X-100 (0.1%). The resultant
supernatant fractions were centrifuged at 353,000 × g for
60 min at 4◦C (Optima TLX Ultracentrifuge, Beckman Coulter,
High Wycombe, United Kingdom). Samples were analyzed by
SDS–PAGE and immunoblotting using mAb 42 and protein
bands quantified by densitometry.
Cells treated with or without LMTM (2 µM) were prepared
similarly for detection of α-Syn mRNA. RNA was extracted from
frozen cell pellets using TRIzol R© (Invitrogen, Thermo Fisher
Scientific, Waltham, MA, United States) and the concentration
measured with a NanoDrop 1000 spectrophotometer (Thermo
Fisher Scientific). RNA (5 µg) was treated with DNase (Applied
Biosystems, Thermo Fisher Scientific), reverse transcribed
with the iScript cDNA synthesis Kit (Bio-Rad, Hercules,
CA, United States) and diluted to a final concentration of
2 ng/µL. Q-RT-PCR was carried out with Maxima SYBR
Green (Applied Biosystems, Thermo Fisher Scientific). The
ratio of h-α-Syn (forward primer: caaaaccaaggagggagtg, reverse
primer: tcttctgggctactgctgtc) to GAPDH (forward primer:
aacgaccccttcattgac, reverse primer: tccacgacatactcagcac) was
calculated with the comparative Ct method and values were
normalized to non-differentiated cells without drug treatment.
Transgenic h-α-Syn Mice and Treatments
Transgenic mice are described in detail elsewhere (Frahm et al.,
2017). L58 and L62 mice overexpress the same full-length h-
α-Syn, described above for cells, fused to a membrane-targeting
N-terminal signal sequence, under control of the mouse Thy1-
promotor. Both male and female homozygous transgenic and
wild-type C57BL/6J litters were housed in small colonies prior
to and during experimentation (up to 6 per cage) in climatised
holding rooms (20◦C and 40% humidity) at 12 h light/dark cycle
(lights on at 6 a.m.) with free access to food and water.
All animal experiments were performed in accordance with
the European Communities Council Directive (63/2010/EU) and
approved by the German Animal Research Ethics Committee of
LAGESO (A0213/13).
Treatment cohorts aged 5–6 months were randomly
assigned to groups based upon body weight and dosed with
LMTM or vehicle via oral gavage, administered daily in the
morning for 6 weeks (6 days per week, Monday–Saturday;
5 ml/kg body weight). Details of test cohorts are shown in
Tables 2, 3. Treatment regime and dose selection was based
TABLE 2 | Treatment groups and cohort sizes (n) used for histopathology in L58
and L62.
Genotype Age at beginning
of study (months)
LMTM dose
(mg MT/kg)
Gender n
L58 5 0 M 5
F 8
L58 5 5 M 7
F 8
L58 5 15 M 7
F 8
L62 5 0 M 7
F 8
L62 5 5 M 6
F 8
L62 5 15 M 7
F 7
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on successful lowering of tau pathology in tau-transgenic
mice (Melis et al., 2015a). LMTM was dissolved in vehicle
(argon-sparged deionised water) and administered within
20 min of dissolution. The doses of LMTM are expressed in
terms of free methylthioninium (MT) base per animal body
weight (mg MT/kg).
Twenty-four hours after the last drug administration,
mice were sacrificed by cervical dislocation; brains were
removed rapidly, the right hemisphere was fixed in formalin,
wax embedded and processed for immunohistochemistry, as
described previously (Melis et al., 2015a,b). The left hemisphere
was frozen rapidly in liquid nitrogen and stored at −80◦C for
α-Syn and MT+ quantification, as described below.
Quantification of α-Syn Proteins in Brain
Tissue
Crushed frozen brain tissue was incubated for 45 min at room
temperature in urea buffer (7 M urea, 2 M thiourea, 70 mM DTT,
25 mM Tris/HCl, 50 mM KCl, 3 mM EDTA, 2.9 mM benzamidine
and 2.1 µM leupeptin) or at 4◦C in Tris-buffer (30 mM; pH 7.5)
and centrifuged for 45 min at 16,000 × g. Protein concentration
in the supernatant fraction was determined using the Bradford
Reagent (Carl Roth, Karlsruhe, Germany). For solubility studies
70 µg of Tris-soluble protein extracts were incubated with 1 µl
PK (Ambion, Thermo Fisher Scientific), diluted to either 1:10,000
or 1:30,000 in PBS, resulting in final activity of 1.2 or 0.4 × 10−6
U PK per µg total brain protein. Digestion was carried out for
15 min at 37◦C and reaction stopped by cooling down on ice.
Protein extracts were separated in 10% Tris-tricine SDS-PAGE,
transferred to PVDF membrane by semi-dry blotting at 4◦C, and
membranes incubated with primary mAb 204, mAb D37A6 and
mAb 3H2897 followed by appropriate secondary antibody (Dako,
Glostrup, Denmark). Chemiluminescent detection was carried
out according to the manufacturer’s instructions (GE Healthcare,
Little Chalfont, United Kingdom). Brain tissue extracts were
analyzed in a different SDS-PAGE system to that used for N1E-
115 cells. The major α-Syn band present in mouse brain and
N1E-115 cells showed identical mobility when separated by
either of the gel systems (not shown). The 19-kDa α-Syn band,
however, migrated with an apparently lower molecular weight
(15 kDa) when separated using the Tris-tricine SDS PAGE system
described in this section.
Immunohistochemistry and Stereological
Cell Counting of Brain Sections
Procedures for staining α-Syn in brain sections were conducted
as described previously (Melis et al., 2015a,b). Brain hemispheres
were coronally sectioned (5 µm) at desired levels. For each
animal, three sections were examined and to avoid re-counting
of the same cell, every fourth section was counted. Sections
were boiled in citric acid-sodium citrate buffer (10 mM; pH
6.0), transferred to peroxidase-blocking solution before mAb 204
and secondary biotinylated antibodies were applied. Thiazin red
(0.001%) was included with primary antibody as an indicator of
aggregation state of α-Syn (Mena et al., 1995, 1996). Sections
were developed in diaminobenzidine solution (Dako) and
counter stained with Ehrlich haematoxylin solution (Carl Roth).
Sections of individual brains were stained simultaneously and
viewed by light microscopy using a Leica DM LB2 or a Zeiss
Axiovert 135 microscope at 50x- to 200x- magnification. α-Syn-
positive cells were counted by an investigator blind to the
experimental details for three sections per animal in the following
regions of interest (Franklin and Paxinos, 2008): Hip+S, auditory
and visual cortices, SNpR, RMC, InG and DpMe+MGV at
Bregma−3.8 mm; MC at Bregma+0.74 mm; and SMC at Bregma
−0.70 mm. Cohort sizes for each drug condition are given in
Table 2.
For PK-digestion studies, sections of cortex on slides were
incubated for 15 min with PK (diluted in PBS to give a final
activity of 1.7 × 10−4 and 3.4 × 10−4 U per slide) at 37◦C
and immunodetection with mAb 204 was conducted thereafter
as described above. For thiazin red staining, cortical sections
were dewaxed, incubated with mAb 204, followed by incubation
in appropriate fluorochrome-conjugated secondary antibody.
Thiazin red solution (0.001%) was applied for 15 min at room
temperature and slides mounted with Gold Antifade Reagent
(Cell Signaling).
Measurement of MT+ Levels in the Brain
Total MT+ level was measured in brain samples by means of a
modified DCE liquid-liquid extraction method (modified from
Peter et al., 2000). Briefly, half brains were homogenized in
3x the weight of water to brain. To a 200-µl sample of brain
homogenate, 250 µl 0.45 M orthophosphoric acid was added and
heated for 30 min at 70◦C; Sodium hexane sulfonate (100 µL;
5% w/v in water) and 0.5 ml DCE were added and the mixture
incubated for 30 min at room temperature. The mixture was
separated by centrifugation and a 300-µl sample of the DCE layer
was dried down and the residue suspended in mobile phase (50:50
water:acetonitrile containing 0.05% formic acid). Total MT+
levels were determined by UPLC with LC-MS/MS detection. The
lower limit of detection was 1 ng/g.
Behavioral Testing
Animal behavior was assessed in the light/dark box. A gray
colored Perspex box (43 cm × 26 cm × 26cm: L ×W × H) was
divided into two equal-sized areas separated by a partitioning wall
containing an aperture to enable free access to either side. One
compartment was covered by a lid (dark zone) while the second
one remained open (light zone). To create a stressful situation,
mice were i.p. injected with saline (0.9%) and immediately
released in one corner of the light compartment and allowed to
explore both compartments freely for 5 min. Ambulation within
the light compartment was recorded by an overhead camera
and analyzed using EthoVision XT10 (Noldus IT, Wageningen,
Netherlands). Dependent variables included time spent in each
compartment (sec), velocity of movement in the light box (cm/s),
cumulative time of immobility (%) and meander as a measure
of path directionality (degree/cm). Behavioral assessment took
place during the last week of drug dosing. The light/dark box was
cleaned using 70% ethanol between subjects. For cohort sizes, see
Table 3.
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TABLE 3 | Treatment groups and cohort sizes (n) used for behavioral assessment.
Genotype Age at beginning
of study (months)
LMTM dose
(mg MT/kg)
Gender n
Wild-type/L62 5.5 0 M 13/13
Wild-type/L62 5.5 1.5 M 14/14∗
Wild-type/L62 5.5 5.0 M 16/12
∗No immunohistochemical analysis available for one mouse receiving 1.5 mg
MT/kg.
Data Analyses
Analysis for stereological cell counting was performed using R
software environment (cell counts; R Development Core Team,
2004), with linear models focussing on the variation between
vehicle group and normalization of output by drug treatment.
The natural logarithm of (cell count+1) was modeled, since it
is more normally distributed. Analyses in Figures 6, 7 were
also performed using R software, again using linear modeling.
All other statistical analyses were conducted using GraphPad
Prism (version 6.00; GraphPad Software Inc., United States).
Data are presented as mean ± SE. Data were analyzed by
Analysis of Variance (ANOVA) and Bonferroni corrected t-test.
Differences were considered to be statistically significant at
p< 0.05.
RESULTS
Aggregated α-Syn Accumulates in
Differentiated N1E-115 Cells Expressing
h-α-Syn
When lysates of N1E-115 neuroblastoma cells were separated
by Tris-glycine SDS-PAGE, no α-Syn was detected using mAb
42 in immunoblots regardless of whether or not cells had been
differentiated (Figure 1A, lanes 1–4). Likewise, the level of
immunoreactivity was minimal in the DH60.21 cell line, derived
from N1E-115 mouse neuroblastoma cells and constitutively
expressing full-length human α-Syn fused with an N-terminal
signal sequence peptide (SSFsyn), in the absence of differentiation
(Figure 1A, lane 5). A mAb 42-reactive band, having a relative
mobility of 19-kDa consistent with h-α-Syn (Jakes et al.,
1994), was detected following differentiation using either serum
depletion alone (Figure 1A, lane 6), or serum depletion plus
either 100 ng/ml NGF (Figure 1A, lane 7), or 1 mM db-cAMP
(Figure 1A, lane 8); the greatest levels were obtained following
differentiation in medium containing 1 mM db-cAMP and 1%
serum. A 50-kDa band was also labeled using mAb 42. This
originates from non-specific antibody binding since no α-Syn
sequence was obtained in this area by mass spectrometry. No
high molecular weight aggregates were observed in lysates, using
SDS-PAGE.
The above findings were consistent with immunocytochemical
studies. Undifferentiated D60.21 cells showed little evidence
of labeling of endogenous α-Syn using several different
anti-α-Syn antibodies (shown for two mAbs in Figure 1B,
upper panel) and the levels were indistinguishable from cells
in which primary antibody had been omitted (data not
shown). α-Syn immunolabelling was substantially increased
following differentiation of D60.21 cells (Figure 1B). The pattern
of immunoreactivity indicated the presence of both diffuse,
cytoplasmic labeling as well as granular labeling around the
nucleus and in the region of the axon hillock (Figure 1B).
LMTM Inhibits h-α-Syn Aggregation in
Differentiated DH60.21 Cells
The level of the 19-kDa h-α-Syn species relative to the
non-specific 50-kDa immunoreactivity was reduced in
differentiated DH60.21 neurons following treatment with
LMTM. A representative immunoblot is shown in Figure 2A.
The EC50 value (±SE) for LMTM was 1.11 ± 0.28 µM (n = 6).
As shown in Figure 2B, LMTM had either no or minimal
effect on expression of h-α-Syn mRNA in undifferentiated and
differentiated neurons, respectively. Baicalein, another inhibitor
of α-Syn aggregation in a cell-free model (Zhu et al., 2004;
Masuda et al., 2006), was also tested in differentiated DH60.21
cells. This also decreased the level of 19-kDa immunoreactivity
retained on the immunoblot, and the corresponding EC50 value
(3.13 ± 1.37 µM [n = 2]) was approximately threefold greater
than with LMTM. Less favorable than baicalein was the efficacy
of the triphenylmethanes Coomassie Brilliant Blue G and R. In
the thioflavin T assay, the EC50 values were 5.4 and 322 µM for
the G and R dyes, respectively (Ahsan et al., 2017).
The state of h-α-Syn expressed in cells was partially
characterized by differential centrifugation and detergent
extraction using Triton X-100 in the presence or absence
of LMTM treatment (Figure 2C). In the absence of Triton
X-100, the majority of h-α-Syn sedimented with low-speed
centrifugation. Cellular membranes and the h-α-Syn in the
low-speed supernatant was largely (80%) sedimentable following
high-speed centrifugation at 353,000 x g for 60 min (11.7
Svedberg units, FP fraction in Figure 2C) consistent with an
implied molecular weight larger than 200 kDa. When Triton
X-100 was included in the extraction, the majority of h-α-Syn was
released into the low-speed supernatant, of which a substantial
portion (36%) remained in an aggregated state sedimenting
in the FP fraction. Following treatment with LMTM in the
absence of Triton X-100, the overall quantity of h-α-Syn was
reduced by approximately 85% and this was found exclusively
in the FP fraction following high-speed centrifugation. When
LMTM treatment was combined with Triton X-100, almost all
of the remaining h-α-Syn was transferred to the high-speed
supernatant (FS) fraction. Quantitative densitometry showed
that levels of the non-specific 50-kDa band were not affected by
the addition of LMTM (data not shown).
LMTM Decreases the Numbers of
α-Syn-Positive Cells in Multiple Brain
Regions
In both L58 and L62 mice expressing full-length α-Syn fused
with a signal peptide, α-Syn immunoreactivity was found
predominantly in pyramidal neurones of the neocortex and
hippocampus, as well as in the principal neurones of the
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FIGURE 1 | α-Syn expression in differentiated neuroblastoma cells as granular
and aggregated α-Syn. (A) N1E-115 cells were transfected with the
constitutive SSFsyn construct containing full-length h-α-Syn fused to a
membrane-targeting signal sequence. Samples were analyzed by SDS-PAGE
and immunodetection of α-Syn using mAb 42. Lanes 1-4, non-transfected
N1E-115 cells; lanes 5-8, DH60.21 cells with SSFsyn. Lanes 1 and 5,
undifferentiated cells grown in the presence of 10% serum; lanes 2 and 6,
cells differentiated by depletion of serum (1%); lanes 3 and 7, cells
differentiated in the presence of 1% serum plus 100 ng/mL NGF; lanes 4 and
8, cells differentiated in medium containing 1% serum plus 1mM db-cAMP.
Non-transfected N1E-115 cells showed no expression of α-Syn even after
differentiation (lanes 1–4). In contrast, transfected DH60.21 cells showed low
(Continued)
FIGURE 1 | Continued
levels of α-Syn expression that increased following differentiation (lanes 6–8),
and the greatest levels were observed following differentiation using db-cAMP
as indicated. (B) Immunocytochemistry of DH60.21 cells before and after
differentiation in the presence of 1% serum plus 1mM db-cAMP. Cells, fixed
with 3% paraformaldehyde, were permeabilised with Triton X-100 and shown
to be labeled by four α-Syn mAbs, as indicated. Images are shown at two
levels of magnification to first demonstrate extent of staining of cells and then,
secondly, to provide detail of granular or fibrillar staining within specific cells.
The epitopes recognized by the mAbs are provided in Table 1.
substantia nigra, the red nucleus, superior colliculus and
geniculate nuclei (Figure 3A). Wild-type mice did not show any
immunoreactivity with any of the antibodies tested (Frahm et al.,
2017). α-Syn immunoreactivity in L62 was more widespread
and affected significantly more cells than in L58 (p < 0.0001,
Figure 3B). In addition to the intraneuronal staining, α-Syn
immunoreactivity was also present throughout the neuropil of
transgenic mice, consistent with its abundance in synapses.
Staining of wild-type mice revealed no such synaptic staining
with mAb 204 (see below).
Levels of endogenous murine α-Syn and transgenic h-
α-Syn were examined by immunoblotting in a urea-soluble
brain extract after low-speed centrifugation using mAbs
D37A6 and mAb 3H2897 to label murine and total α-Syn,
respectively. Overall, both genotype and age-effects were
significant (p < 0.001). There was no increase in murine
α-Syn levels in either L58 or L62 relative to wild-type
controls at 6–7 months or 12–13 months. However, total
brain α-Syn was significantly increased in older L62 mice
(p< 0.001), implying that the age-dependent increase was due to
accumulation of the transgenic h-α-Syn in brain (Figures 3C,D).
In L58 mice, age-related accumulation of total α-Syn was
less pronounced and not statistically significant, although
distinct from wild-type mice at 12–13 months (Figure 3D,
p< 0.05).
Immunohistochemistry using mAb 204 showed diffuse
granular and perinuclear labeling, as well as more homogeneous
labeling in the cell body of some neurones. The latter were
dual labeled with thiazin red, implying transition to fibrillar
aggregates (Mena et al., 1995, 1996). (Figure 3E). In order
to confirm whether the aggregation detected histologically
was associated with increased resistance to proteases, Tris-
soluble protein lysates were treated with PK. A large amount
of Tris-soluble h-α-Syn remained intact while ß-actin was
completely cleaved (Figure 3F). Following similar treatment
of histological sections using higher concentrations of PK,
both the diffuse granular and somatic α-Syn remained intact
(Figure 3G).
Having established a progressive histopathological phenotype
in both L58 and L62 mice, we examined the effect of LMTM
in these mice after oral treatment at 5 and 15 mg MT/kg/day
for 6 weeks. No adverse effects were observed at either dose,
although L62 mice had reduced body weight gain at the
higher dose (Figure 4). The mean brain levels of MT+ were
30.62 ± 27.34 ng/g, and 100.49 ± 95.16 ng/g for the 5 and 15 mg
MT/kg doses, respectively.
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FIGURE 2 | LMTM treatment decreased expression and altered solubility of
the h-α-Syn. (A) DH60.21 cells were differentiated in medium containing 1%
serum and 1 mM db-cAMP in the presence of LMTM, as indicated, for 3 days
in triplicate. The amount of h-α-Syn on immunoblots decreased with
increasing concentrations of LMTM. (B) Cells treated with or without LMTM
(2 µM) were prepared similarly for detection of α-Syn mRNA. RNA was
extracted from frozen cell pellets by TRIzol and quantified by Maxima SYBR
Green. The relative level of α-Syn m-RNA was normalized to GAPDH and
values are expressed as mean ± SE. (C) For the analysis of protein solubility,
differentiated DH60.21 cells were treated in the presence or absence of 2 µM
LMTM for 3 days. α-Syn was extracted in Tris buffer in the absence or
presence of 0.1% Triton X-100 and cell debris sedimented by low-speed
centrifugation. The resultant supernatant was subjected to centrifugation at
353,000 × g for 60 min to provide fast supernatant (FS) and fast pellet (FP)
fractions. Samples for (A,C) were analyzed using Tris-glycine SDS-PAGE and
immunodetection of α-Syn using mAb 42.
WT mice had no α-Syn-reactive cells nor any synaptic staining
(Figure 5) and the number of α-Syn-reactive cells and the level
of synaptic staining in L58 and L62 mice were qualitatively
decreased after LMTM treatment (Figure 5). The number of
α-Syn-reactive cells was decreased significantly after treatment
with LMTM at both doses, and the extent of reduction was
comparable for both cortical and sub-cortical regions (Figure 6
and Table 4). The decrease was greater in L58 than in L62 and,
in L62, was greater in females than in males. Expressed as log(cell
count + 1), the effect sizes at each dose for L58 were −0.61 and
−0.96 and for L62 were −0.47 and −0.48 for doses of 5 and
15 mg MT/kg, respectively). These represent reductions in the
range of 38–63%, when L58 and L62 are both considered, relative
to vehicle-treated controls.
LMTM Targets Anxiety and
Movement-Related Aspects in a
Synucleinopathy Mouse Model
Behavioral effects of LMTM treatment were examined in L62
only. Transgenic mice and wild-type controls were assessed
behaviorally in the light/dark box following oral treatment with
LMTM (1.5 and 5 mg MT/kg) for 6 weeks. Compared to wild-
type controls, vehicle-treated L62 mice spent more time in
the illuminated compartment of the light/dark box (maximum
time 300 s; Figure 7A; ∗∗∗p < 0.001), had reduced speed of
movement (Figure 7B; ∗∗∗p < 0.0001), were immobile longer
in the light zone (Figure 7C; ∗∗∗p < 0.001) and showed greater
stereotypic meandering (Figure 7D; ∗∗p < 0.01). WT control
mice showed a dose-dependent increase in time spent in the
light zone (∗p < 0.05; dose-dependent), but effects on the other
parameters tested were not significant. L62, on the other hand,
showed a significant dose-dependent reduction in time spent in
the light zone (Figure 7A; ∗p < 0.05). The treatment effects on
other parameters were in the direction of normalization behavior,
particularly for the 5 mg MT/kg dose.
There was an association between the beneficial effects
of treatment on behavior and the decrease in numbers of
α-Syn-positive cells at both active doses (Figure 8; ∗∗∗p< 0.0001
for 1.5 mg MT/kg and ∗∗p< 0.01 for 5 mg MT/kg, with respective
effect sizes of −0.42 and −0.35 in units of log(cell count+ 1)).
The effects of LMTM were generally comparable at the two
doses, both in terms of behavioral rescue and reduction in α-Syn
pathology.
DISCUSSION
We report the development of two novel model systems for
testing the efficacy of synuclein aggregation inhibitors as a
potential treatment for diseases characterized by pathological
aggregation of synuclein, particularly PD and dementia with
Lewy bodies. In these diseases, synuclein pathology spreads from
brainstem, via the midbrain to neocortex, with development
of symptom profiles corresponding to the spread of pathology
(Braak and del Tredici, 2016). The formation of pathological
aggregates after initial seeding or nucleation, and subsequent
prion-like spread of pathology is emerging as a common
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FIGURE 3 | α-Syn expression in transgenic mice increased with age and was greatest in L62 mice. (A) Expression of h-α-Syn in L62 was greater than in L58.
Representative microphotographs taken from primary motor cortex, hippocampal CA1/CA3 and entorhinal cortex revealed differential α-Syn immunoreactivity (mAb
204) between transgenic lines aged 6 months. (B) Quantification of α-Syn positive cells (mean ± SE) in the right hemisphere of the midbrain using mAb 204,
showing more than twofold greater number of cells with h-α-Syn inclusions in L62 than in L58 mice aged 6 months (unpaired Student t-test: ∗∗∗p < 0.0001).
(C) Assessment of total and murine α-Syn (normalized to β-actin loading) in L58 and L62 mice using immunoblots revealed unchanged murine α-Syn levels in either
line but a progressive increase in total α-Syn in both lines between 6 and 12 months due to the build-up of transgenic human α-Syn, with a greater accumulation of
α-Syn in L62 than in L58, as shown by densitometric quantification of α-Syn normalised to β-actin in (D). Values are expressed as mean ± SE. Bonferroni post-test:
∗p < 0.05 and ∗∗∗p < 0.001 for genotype effect and §§§, p < 0.001 for age effect. (E) Representative images for L62 motor cortex sections co-stained with
anti-α-Syn mAb 204 (left) and thiazin red (middle), showing a neuron positive for α-Syn (arrow) and another neuron in which α-Syn inclusions were co-labelled with
thiazin red (asterisk). (F) Tris-soluble monomeric α-Syn was resistant to PK cleavage, whereas β-actin was not. (G) Representative images for L62 motor cortex
sections stained with mAb 204 treated with PK prior to antibody reaction show cytoplasmic and synaptic α-Syn inclusions resistant to PK cleavage. Samples for
(C,F) were analyzed using Tris-tricine SDS-PAGE and immunodetection of α-Syn using mAb 204 (h-α-Syn), mAb D37A6 (mouse α-Syn) and mAb 3H2897 (total
α-Syn). Scale bars, 100 µm.
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FIGURE 4 | LMTM was tolerated by mice. Effect of LMTM on body weight for
L58 and L62 mice is shown. Body weight gain/loss is expressed as the mean
percentage change (±SE) over 6 weeks relative to the start of treatment. Drug
exposure did not differ from vehicle for either genotype but there was a
significant difference (p = 0.04) in body weight gain between vehicle-treated
mice for both lines.
theme for a group of progressive neurodegenerative protein
misfolding disorders which also include Alzheimer’s disease
and Huntington’s chorea (Lee S.J. et al., 2010). Inhibition
of pathological aggregation provides a rational therapeutic
approach for these diseases, with a view to limiting both
the direct toxic effects of aggregates and their prion-like
spread. We have previously reported that the methylthioninium
moiety (MT) acts as an inhibitor of tau protein aggregation
in cell-free and cell-based models in vitro (Harrington et al.,
2015). We have also shown that MT reduces tau aggregation
pathology and normalizes behavioral deficits in tau transgenic
mouse models (Melis et al., 2015a). These studies formed
the basis for clinical trials in AD first using the oxidized
form of MT (present in methylthioninium chloride, MTC,
commonly known as methylene blue) (Wischik et al., 2015),
and then the stable reduced form (LMTM). The latter was
developed to overcome the absorption limitation of MTC, and
was found to have potential efficacy on clinical and brain
imaging endpoints as monotherapy even at a dose as low
as 4 mg twice a day (Gauthier et al., 2016; Wilcock et al.,
2018).
Cell-based models of aggregation provide an important
intermediate testing platform which permit determination of
activity and toxicity within the milieu of the living cell. We
previously reported that pathological aggregation and truncation
of tau protein could be induced using a fusion construct
incorporating a signal sequence which directs the protein to the
endoplasmic reticulum (Harrington et al., 2015). This redirection
is considered to enhance the seeding of aggregation by providing
an initial abnormal binding substrate (Lai et al., 2016). Because
of the inherent toxicity of the aggregates produced, generation of
stable cell lines requires a combination of low level constitutive
expression of the protein and a further intervention which
increases expression levels and aggregation in a controlled
manner which permits drug testing. In the case of α-Syn, we
found that it is possible to express an aggregation-prone construct
constitutively at low levels in the N1E-115 mouse neuroblastoma
cell line, and to induce aggregation following differentiation.
There have been similar findings reported for SH-SY5Y
neuroblastoma cells overexpressing α-Syn, where differentiation
was required to generate inclusion bodies (Hasegawa et al.,
2004). In the NIE-derived model, differentiation is associated
with a substantial increase in the level of expression of h-α-Syn
mRNA and a corresponding increase in the level of h-α-Syn
protein. Labeling with anti-α-Syn antibodies showed the presence
of granular synuclein aggregates in a perinuclear location,
in the axon hillock and diffusely throughout the cytoplasm
following differentiation. The sedimentation characteristics of
the aggregates were consistent with the formation of decamers
or greater oligomers with a molecular weight greater than
200 kDa.
Treatment with LMTM decreased the overall quantity of
SDS-soluble α-Syn retained on immunoblots with an EC50 of
about 1 µM, and largely eliminated the high molecular weight
oligomers from the high-speed pellet. Baicalein, previously
reported to have anti-aggregation properties for synuclein (Zhu
et al., 2004; Hu et al., 2016), produced similar effects in this
cell model, except with a higher EC50 of about 3 µM. We have
also previously reported similar results for LMTM using signal
sequence fusion constructs of tau protein (Harrington et al.,
2015). Therefore, the fusion protein construct provides a useful
means of inducing α-Syn aggregation at the cellular level, and
this aggregation can be blocked by LMTM at concentrations
consistent with dosing in vivo.
Based on the cell model findings, we developed two
corresponding transgenic mouse models, L58 and L62. L62
had higher brain levels of α-Syn and more widespread
pathology. The level of α-Syn found in the brain also increased
in an age-dependent manner. Using differential labeling for
endogenous mouse and total α-Syn, we found that the
age-dependent increase was due to selective accumulation of the
human form in L62. The aggregates were found predominantly
in the pyramidal cells of the cortex, and in the principal cells
of a number of subcortical nuclei. The immunohistochemical
features of the aggregates were similar to those produced in the
NIE-derived cell line, with granular perinuclear aggregates and
more diffuse cytoplasmic labeling which could be double labeled
with thiazin red with sufficiently high levels of aggregation
suggesting a transition to fibrillar forms (Mena et al., 1995,
1996). We further confirmed that the aggregates produced in the
brain were more resistant to PK than actin, a finding previously
reported in other transgenic synuclein mouse models.
As found in the cell model, treatment with LMTM resulted in
an overall decrease in levels of α-Syn aggregation pathology, in
the range of 38–63% compared with vehicle-treated animals. The
effect of treatment was greater in the less severely affected L58
and, in L62, the effect was greater in females. These beneficial
effects on pathology were associated with normalization of
the abnormal behavioral phenotype seen in L62 mice which
is described more fully in a separate report (Frahm et al.,
2017). L62 mice are characterized by general poverty of
movement, seen as longer time spent in the light zone of a
light/dark box, longer periods of immobility in the light zone,
reduced speed of movement, and greater stereotypic meandering
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FIGURE 5 | LMTM decreased α-Syn pathology in L58 and L62 mice. Representative immunohistochemical images of the motor cortex (MC) and striatum for
vehicle- (A) and LMTM-treated (B,C) mice. WT mice were devoid of synuclein immunoreactivity. L58 and L62 showed both neuronal α-Syn inclusions and extensive
synaptic content; that were both decreased with increasing dose in these representative blots. Scale bar, 100 µm.
movement, all of which were to varying extents reversed by
treatment with LMTM. Direct comparison of the effects of
LMTM at 1.5 and 5 mg/day again confirmed a lack of dose
response on behavior, and an association between effects on
pathology and behavior compared with vehicle-treated control
mice.
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FIGURE 6 | LMTM decreased α-Syn pathology in L58 and L62 mice in multiple brain regions. LMTM significantly lowered the number of mAb 204-immunoreactive
α-Syn-positive cells in multiple brain regions in L58 and L62 mice of both sexes. Values are expressed as mean log(count +1) (±SE).
Although LMTM dosing at 5 and 15 mg/day produced
a threefold difference in brain levels of MT, there was no
evidence of a dose-response for effect on pathology. There
appears therefore to be an overall lack of dose-response over a
10-fold dosing range from 1.5 to 15 mg MT/kg. This lack of
dose-response was also found for tau pathology in tau transgenic
mouse models using LMTM, where there was even evidence of
a negative dose-response at 45 mg MT/kg (Melis et al., 2015a).
Indeed, the same lack of dose-response was also found in a
recent clinical trial over a 30-fold dosing range of 8 mg/day to
250 mg/day. This suggests that, at least in the brain, the effect of
treatment depends on reaching a critical threshold concentration
of MT beyond which there is no advantage to using higher
doses. It is possible from this study to estimate this threshold as
approximately 15 ng MT/g (0.05 µM MT). Interestingly, this is
also the concentration required for enhancement of autophagy
TABLE 4 | Effect size for LMTM on α-Syn pathology∗.
Genotype LMTM dose (mg MT/kg) Sex Effect size SE p-value
L58 5 F −0.67521 0.081539 2.443e-16∗∗∗
L58 15 F −1.08321 0.078948 <2.2e-16∗∗∗
L58 5 M −0.54608 0.092228 3.861e-09∗∗∗
L58 15 M −0.82816 0.098710 <2.2e-16∗∗∗
L58 5 Mean −0.61064 0.059163 <2.2e-16∗∗∗
L58 15 Mean −0.95569 0.058661 <2.2e-16∗∗∗
L62 5 F −0.72698 0.079024 <2.2e-16∗∗∗
L62 15 F −0.56317 0.083936 2.651e-11∗∗∗
L62 5 M −0.21098 0.086082 0.01435∗
L62 15 M −0.39943 0.081572 1.067e-06∗∗∗
L62 5 Mean −0.46898 0.055217 <2.2e-16∗∗∗
L62 15 Mean −0.48130 0.054266 <2.2e-16∗∗∗
∗Effect size, expressed as log(count+1), shown for means over all regions in individual transgenic lines (mean effect in male and female) and in individual genders.
∗p < 0.05; ∗∗∗p < 0.001.
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FIGURE 7 | LMTM rescued behavioral deficiencies seen in L62 mice during the light/dark box testing. L62 mice expressed an anxiolytic phenotype as measured by
four parameters: (A) Time spent in the illuminated compartment of the light/dark box; (B) speed of movement; (C) immobility; and (D) meander as a stereotypic trait.
The phenotype observed in L62 mice was attenuated with LMTM at doses of ≥1.5 mg MT/kg, with the exception of meander, where the difference remained
significant at the 1.5 mg MT/kg dose. However, WT controls also were affected by the administration of MT, but this was only significant for the proxy ‘duration in
light zone’. For details, see Results.
(Congdon et al., 2012) and of oxidative phosphorylation by
mitochondria (Zhang et al., 2006), although much lower than the
EC50 found in the NIE cell line. This suggests that the cell model,
although useful for predicting efficacy in vivo, may over-estimate
the concentration required for activity in the much more complex
milieu of the whole brain.
α-Syn has been expressed in various forms in transgenic
mice. There are transgenic mice expressing full-length α-Syn
containing those point mutations (A53T, A30P or E46K)
(Sommer et al., 2000; Rockenstein et al., 2002; Piltonen et al.,
2013; Deusser et al., 2015; Mbefo et al., 2015) found in
dominant familial PD (Dauer and Przedborski, 2003). Expression
of wild-type h-α-Syn in mice has been achieved under the
regulatory control of either the platelet-derived growth factor B
or Thy1-promotors (Masliah et al., 2000; van der Putten et al.,
2000). The loss of dopaminergic cells and presence of α-Syn
inclusions in neurons was directly correlated with the level
of h-α-Syn transgene expression (Masliah et al., 2000; van
der Putten et al., 2000). Although the α-Syn transgene in
this study was expressed in various brain regions relevant to
parkinsonian phenotypes, there was no frank cell loss in the
substantia nigra (Frahm et al., 2017). This is consistent with
the finding that overexpression of C-terminally truncated α-Syn
(residues 1–120) in mice leads to pathological changes in the
nigrostriatal projections, without any associated cell loss in the
pars compacta by 12 months (Tofaris et al., 2006). Moreover,
global expression of protein throughout the brain is a feature of
the Thy1-promotor when used as a regulatory element to drive
the α-Syn transgene expression (Kahle et al., 2002; Rockenstein
et al., 2002; Magen et al., 2012; Delenclos et al., 2014) and L58 and
L62 mice in this study expressed α-Syn in brain stem, cortical and
subcortical structures.
Mouse models of wild-type and mutant α-Syn presenting
with neurodegeneration have been proposed as suitable for the
development and assessment of disease-modifying therapies for
idiopathic PD and dementia with Lewy bodies (Allain et al.,
2008). There has been particular interest to intervene with the
misfolding and oligomerisation α-Syn using antibodies to reduce
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FIGURE 8 | Behavioral rescue with LMTM is concomitant with decrease in immunoreactive α-Syn inclusions. The four behavioral parameters measured in the
light/dark box are compared as a function of mAb 204-reactive α-Syn pathology in motor cortex of L62 mice: (A) duration in light zone; (B) speed; (C) time immobile
in light zone and (D) meander. There was a significant decrease in numbers of α-Syn-positive cells at both doses (∗∗∗p < 0.0001 for 1.5 mg MT/kg; ∗∗p < 0.01 for
5 mg MT/kg). The decrease in α-Syn-reactive cells was associated with an improvement of the anxiolytic measures. The effect observed with 5 mg MT/kg did not
exceed that observed with 1.5 mg MT/kg, with the exception of the parameter ‘meander’ (D).
the α-Syn burden in transgenic mice (Bae et al., 2012; Lindström
et al., 2014; Mandler et al., 2014; Tran et al., 2014) and to
prevent the cell-to-cell transmission of α-Syn between neurons
(Desplats et al., 2009; Danzer et al., 2012; Luk et al., 2012).
Alternative strategies include the drug-induced increase of α-Syn
clearance through enhancement of proteasomal or lysosomal
activation (Lee B.H. et al., 2010), or by stimulation of autophagy
(Dehay et al., 2015). Targeting α-Syn disaggregation (Sivanesam
et al., 2015) is not without risk given the fact that oligomeric
proteins are considered neurotoxic and fibril formation may be
a safe way for disposal of oligomers. Nevertheless, there are
several compounds that inhibit α-Syn aggregation in vitro (Zhu
et al., 2004; Masuda et al., 2006; Wagner et al., 2013; Ibrahim
and McLaurin, 2016) and which demonstrate activity in vivo
using mouse models of PD (Hu et al., 2016; Tatenhorst et al.,
2016). There was no evidence of increased general toxicity or
neurotoxicity for LMTM over a 10-fold dosing range up to 15 mg
MT/kg.
The combination of beneficial effects on pathological
aggregation of α-Syn, enhancement of autophagy
(Congdon et al., 2012) and enhancement of mitochondrial
respiration makes LMTM a particularly interesting candidate
for further clinical study in both PD and dementia with Lewy
bodies. The toxicology of LMTM has been well characterized in
preclinical studies, and a relatively benign safety profile of LMTM
has been well documented now in Phase 2 and Phase 3 trials
(Wischik et al., 2015; Gauthier et al., 2016; Wilcock et al., 2018).
The animal safety data available from the present study adds to
this assessment, particularly if the low dose of 1.5 mg MT/kg/day
identified as being an effective dose in vivo translates to the
human clinical context. LMTM may therefore have potential as a
disease-modifying treatment for synucleinopathies including PD
and dementia with Lewy bodies which now requires to be tested
in clinical trials.
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